Erectile dysfunction and cognitive decline may seem like unrelated problems, but both depend partly on healthy blood vessels, intact nerve signaling, and stable metabolic health. Longitudinal studies have found that worsening erectile function can accompany later declines in memory or processing speed. That does not mean erectile dysfunction causes dementia. It does mean that a persistent change in erections may deserve attention as part of a broader health assessment rather than being treated as an isolated quality-of-life issue.
Erectile Dysfunction and Cognitive Decline in Population Studies
The strongest evidence for a connection comes from observational studies that follow men over time. In the Vietnam Era Twin Study of Aging, researchers assessed 818 men at average ages of approximately 56, 61, and 68. Lower erectile function at baseline was associated with poorer performance across cognitive domains and faster decline in processing speed. Within-person decreases in erectile function were also associated with declines in episodic memory, even after adjustment for demographic and health factors.[1]
An earlier analysis of older men found a similar pattern. Hsu and colleagues reported that declines in erectile function and sexual activity were associated with declining Mini-Mental State Examination scores. Men who had erectile dysfunction or were sexually inactive at baseline were also more likely to show cognitive decline during follow-up.[2] These findings are valuable because they track change over time, but they still cannot determine whether one condition directly causes the other.
Large health-record studies have examined diagnosed dementia as an outcome. A Taiwanese population-based cohort compared 4,153 men with newly diagnosed erectile dysfunction with 20,765 matched controls. Over seven years, dementia incidence was 35.33 per 10,000 person-years in the erectile dysfunction group and 21.67 per 10,000 person-years among controls. After adjustment for several medical and socioeconomic factors, erectile dysfunction was associated with a 68% higher relative risk of dementia.[3]
Relative risk needs context. Only 2.5% of men with erectile dysfunction in that cohort developed dementia during follow-up, compared with 1.5% of controls. The association is therefore not a diagnosis or a prediction for an individual man. It is a population-level signal that may reflect shared underlying disease.
The Shared Vascular Pathway
An erection is a vascular event. Sexual stimulation triggers nitric oxide release, relaxation of smooth muscle in penile arteries, increased inflow of blood, and temporary restriction of venous outflow. Endothelial cells lining the arteries help regulate this process. Hypertension, diabetes, smoking, high cholesterol, obesity, and physical inactivity can impair endothelial function and reduce nitric oxide availability.
The brain is also highly dependent on its small blood vessels. Chronic injury to the cerebral microcirculation can contribute to white-matter damage, small infarcts, and vascular cognitive impairment. Penile arteries are smaller than coronary or many cerebral arteries, so vascular dysfunction may become clinically visible through erection changes before symptoms appear in other organs. This is sometimes described as an “artery-size” hypothesis: the same systemic vascular burden may become symptomatic earlier in a smaller vessel bed.
This model is biologically plausible, but it should not be oversimplified. Alzheimer disease is not purely a vascular disorder, and erectile dysfunction has many nonvascular causes. Still, shared endothelial and microvascular dysfunction provide a reasonable explanation for some of the statistical overlap between erectile and cognitive outcomes.
Inflammation and oxidative stress may also connect the two conditions. Both can reduce nitric oxide signaling, damage vessel walls, and accelerate atherosclerosis. Insulin resistance adds another layer by affecting endothelial function, testosterone regulation, and cerebral metabolism. For this reason, an evaluation of persistent erectile dysfunction often includes attention to blood pressure, glucose regulation, lipids, waist circumference, and smoking status.
Nerves, Hormones, Medications, and Mental Health
Not every connection between erections and cognition runs through the arteries. Erectile function requires coordinated signaling among the brain, spinal cord, peripheral nerves, blood vessels, and endocrine system. Neurologic disorders can disturb arousal, autonomic signaling, sensation, or motor function. Cognitive symptoms and sexual dysfunction may therefore arise from the same neurologic process without either symptom causing the other.
Hormonal disorders can also affect both domains. Markedly low testosterone may reduce libido and contribute to erectile symptoms, although testosterone is not the sole determinant of erection quality. Thyroid disease, elevated prolactin, and poorly controlled diabetes can alter sexual function and sometimes affect attention, energy, or mood. Laboratory testing should be selected from the history and examination rather than ordered indiscriminately.
Medication effects deserve a careful review. Some antidepressants, antipsychotics, sedatives, opioid pain medicines, and blood-pressure drugs can affect sexual function. Anticholinergic medicines and sedatives may also impair cognition, especially in older adults. Men should not stop prescribed medication on their own; a clinician can determine whether the timing, dose, or choice of drug may be relevant.
Depression is another important confounder. It can lower sexual desire, impair erection quality, reduce concentration, and produce subjective memory complaints. Anxiety about sexual performance may amplify erectile difficulty, while distress over repeated erectile problems can worsen mood. A complete assessment should consider sleep, alcohol or substance use, relationship factors, and mental health alongside vascular disease.
What Studies of PDE5 Inhibitors Can and Cannot Tell Us
Phosphodiesterase type 5 inhibitors improve erectile response by slowing the breakdown of cyclic guanosine monophosphate, a messenger involved in nitric-oxide-mediated smooth-muscle relaxation. Because PDE5 signaling also has vascular and neurologic relevance, researchers have asked whether these medicines are associated with cognitive outcomes.
A 2024 UK cohort study included 269,725 men aged 40 or older with newly diagnosed erectile dysfunction. During a median 5.1 years of follow-up, men who initiated a PDE5 inhibitor had a lower recorded incidence of Alzheimer disease than nonusers, with an adjusted hazard ratio of 0.82. Stronger associations appeared among men receiving more prescriptions.[4] A separate US database study published in 2025 reported lower three-year dementia risk among men with erectile dysfunction who received tadalafil or sildenafil.[5]
These results are hypothesis-generating, not proof that PDE5 inhibitors prevent dementia. Men who seek and continue treatment may differ from nonusers in income, healthcare engagement, physical activity, relationship status, or baseline health. Prescription records do not establish that medication was taken, and dementia diagnoses in electronic records may be incomplete. “Healthy-user” bias and residual confounding can remain even after statistical adjustment.
The same caution applies to reverse-direction research. A 2024 Mendelian randomization analysis suggested that genetic liability to Alzheimer disease may modestly increase erectile dysfunction risk independent of measured cardiovascular disease.[6] Mendelian randomization can reduce some forms of confounding, but its conclusions depend on assumptions about the genetic instruments and do not establish what will happen to a particular patient.
PDE5 inhibitors should be prescribed for an appropriate clinical indication, not used as self-directed cognitive prevention. They can interact dangerously with nitrate medications and require individualized review in men with certain cardiovascular conditions, low blood pressure, or other contraindications.
When Erectile Changes Warrant a Broader Evaluation
Occasional erection difficulty is common and may follow stress, fatigue, heavy alcohol use, or relationship strain. A consistent change lasting several weeks or months warrants a clinical conversation, particularly when it is new, progressive, or accompanied by reduced exercise tolerance, chest discomfort, neurologic symptoms, or changes in memory and daily functioning.
A clinician may ask about the onset and pattern of symptoms, morning erections, libido, medication use, sleep, mood, and cardiovascular risk. Blood pressure measurement and a focused cardiovascular, neurologic, and genital examination may be appropriate. Depending on the individual, testing may include fasting glucose or hemoglobin A1c, a lipid profile, and morning testosterone. Cognitive screening is not automatically necessary for every man with erectile dysfunction, but persistent memory concerns that interfere with work, finances, medication management, driving, or familiar tasks should be evaluated.
Sudden focal neurologic symptoms—including facial droop, arm weakness, speech difficulty, loss of balance, or an abrupt severe headache—require emergency care. New chest pressure, shortness of breath, or fainting with sexual activity also requires urgent assessment. Erectile dysfunction itself is usually not an emergency, but it can provide an opportunity to identify modifiable vascular risks before a more serious event occurs.
Risk reduction focuses on established health measures rather than unproven dementia-prevention claims. Regular aerobic and resistance exercise, smoking cessation, adequate sleep, moderation of alcohol, and treatment of hypertension, diabetes, and dyslipidemia may support both vascular and cognitive health. A Mediterranean-style dietary pattern is reasonable for overall cardiovascular risk reduction. These steps may support erectile function, but individual response varies and they do not replace indicated medical treatment.
Conclusion
Research consistently identifies an association between erectile dysfunction and cognitive decline, but association is not destiny and does not establish causation. The most likely explanation involves overlapping vascular, metabolic, neurologic, medication, and psychological factors. Persistent erectile changes should prompt a proportionate health review—not fear—because they may reveal treatable risks affecting the heart, brain, and sexual function.
For more evidence-based men's health information, visit the OnyxMD blog. If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including EPIQ CHEWS, starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Slayday RE, Bell TR, Lyons MJ, et al. Erectile function, sexual satisfaction, and cognitive decline in men from midlife to older adulthood. The Gerontologist. 2023;63(2):382–394. doi:10.1093/geront/gnac151
- Hsu B, Hirani V, Naganathan V, et al. Temporal associations between sexual function and cognitive function in community-dwelling older men: the Concord Health and Ageing in Men Project. Age and Ageing. 2018;47(6):900–904. doi:10.1093/ageing/afy088
- Yang CM, Shen YC, Weng SF, et al. Increased risk of dementia in patients with erectile dysfunction: a population-based, propensity score-matched, longitudinal follow-up study. Medicine (Baltimore). 2015;94(24):e990. doi:10.1097/MD.0000000000000990
- Adesuyan M, Jani YH, Alsugeir D, et al. Phosphodiesterase type 5 inhibitors in men with erectile dysfunction and the risk of Alzheimer disease. Neurology. 2024;102(7):e209131. doi:10.1212/WNL.0000000000209131
- Kloner RA, Stanek E, Crowe CL, et al. Benefits of tadalafil and sildenafil on mortality, cardiovascular disease, and dementia. The American Journal of Medicine. 2025;138(3):441–448.e3. doi:10.1016/j.amjmed.2024.10.039
- Liao K, Lou Q. Alzheimer's disease increases the risk of erectile dysfunction independent of cardiovascular diseases: a Mendelian randomization study. PLOS ONE. 2024;19(6):e0303338. doi:10.1371/journal.pone.0303338
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.